Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion

Experimental and Therapeutic Medicine

Volumn 5, Issue 3, 2013, Pages 783-788

  Wei, Jinru ^a   Tang, Quan ^a   Liu, Lijuan ^a   Bin, Jianbin ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Coronary heart disease; Diabetes mellitus; Inflammatory cytokine; Peroxisome proliferator activated receptor ; Peroxisome proliferator activated receptor

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROTEIN SECRETION; STENOSIS; VENOUS BLOOD;

EID: 84873195909     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.891     Document Type: Article

References (33)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
2. Shirani J and Dilsizian V: Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome? Curr Cardiol Rep 12: 140-146, 2010.
3. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
4. Becker J, Delayre-Orthez C, Frossard N and Pons F: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 20: 429-447, 2006.
5. Calkin AC and Thomas MC: PPAR agonists and cardiovascular disease in diabetes. PPAR Res 2008: 245410, 2008.
6. Inoue I, Goto S, Mizotani K, et al: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863-876, 2000.
7. Staels B, Koenig W, Habib A, et al: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793, 1998.
8. Turay J, Grniaková V and Valka J: Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate. Drugs Exp Clin Res 26: 83-88, 2000.
9. Marx N, Sukhova G, Murphy C, Libby P and Plutzky J: Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153: 17-23, 1998.
10. Jiang C, Ting AT and Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86, 1998.
11. Delerive P, De Bosscher K, Besnard S, et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274: 32048-32054, 1999.
12. Chakrabarti R, Vikramadithyan RK, Misra P, et al: Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140: 527-537, 2003.
13. Mittra S, Sangle G, Tandon R, et al: Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol 150: 480-487, 2007.
14. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA and Thomas MC: Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17-22, 2007.
15. Calkin AC, Cooper ME, Jandeleit-Dahm KA and Allen TJ: Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49: 766-774, 2006.
16. Calkin AC, Forbes JM, Smith CM, et al: Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25: 1903-1909, 2005.
17. Nissen SE, Wolski K and Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581-2586, 2005.
18. Tordjman K, Bernal-Mizrachi C, Zemany L, et al: PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107: 1025-1034, 2001.
19. Mardones P, Pilon A, Bouly M, et al: Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 278: 7884-7890, 2003.
20. Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002.
21. Saha SA, Kizhakepunnur LG, Bahekar A and Arora RR: The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 154: 943-953, 2007.
22. Zeng X, Dai J, Remick DG and Wang X: Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res 93: 311-320, 2003.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
24. Laakso M: Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942, 1999.
25. Tenenbaum A, Motro M, Fisman EZ, et al: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197-2202, 2004.
26. Jones IR, Swai A, Taylor R, Miller M, Laker MF and Alberti KG: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 13: 855-863, 1990.
27. Sobel BE: Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 120 (9 Suppl 2): S3-S11, 2007.
28. Liuzzo G, Goronzy JJ, Yang H, et al: Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101: 2883-2888, 2000.
29. Chinetti G, Fruchart JC and Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol 90 (Suppl 3): 125-132, 2001.
30. Wang G, Wei J, Guan Y, Jin N, Mao J and Wang X: Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism54: 590-597, 2005.
31. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF and Lee YT: Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170: 315-323, 2003.
32. Han SH, Quon MJ and Koh KK: Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46: 1086-1092, 2005.
33. Mohanty P, Aljada A, Ghanim H, et al: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89: 2728-2735, 2004.